Tina Morgan Ross

USPTO Granted Patents = 24 (Patent Applications = 6)

CIPO Patents = 2

EPO Patents = 7 (Patent Applications = 6)

Average Co-Inventor Count = 7.1

ph-index = 7

Forward Citations = 183(Granted Patents)

Location History:

Anderson, PA (US) (1999)
Audubon, PA (US) (1996 - 2006)
Royersford, PA (US) (2009 - 2013)
Royerford, PA (US) (2006 - 2014)

Company Filing History:

9 out of 2,078

Janssen Pharmaceutica Nv

patents

5 out of 1,152

Vertex Pharmaceuticals, Inc.

patents

4 out of 363

Ortho-mcneil Pharmaceutical Corp.

patents

4. 2 out of 4,948

Hoffmann-la Roche Inc.

Sterling Winthrop Inc.

Years Active: 1996-2014

Loading Chart...

24 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8778956 - Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders (2014-07-15),

2. 8530475 - Bridged aryl piperazines derivatives useful for the treatment of CNS, GI-urinary and reproductive disorders (2013-09-10),

3. 8383637 - 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE) (2013-02-26),

4. 8354444 - Substituted pyrrolidine-2-carboxamides (2013-01-15),

5. 8076358 - 6-substituted-thio-2-amino-quinoline derivatives useful as inhibitors of β-secretase (BACE) (2011-12-13),

6. 8017607 - N-substituted-pyrrolidines as inhibitors of MDM2-P-53 interactions (2011-09-13),

7. 7868022 - 2-amino-quinoline derivatives useful as inhibitors of β-secretase (BACE) (2011-01-11),

8. 7786116 - 2-amino-quinoline derivatives useful as inhibitors of β-secretase (BACE) (2010-08-31),

9. 7582649 - Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders (2009-09-01),

10. 7531545 - 2-amino-3,4-dihydro-pyrido[3,4-d]pyrimidine derivatives useful as inhibitors of β-secretase (BACE) (2009-05-12),

11. 7081463 - Hydroxy alkyl substituted 1,3,8-Triazaspiro[4.5]decan-4-one derivatives useful for the treatment of orl-1receptor mediated disorders (2006-07-25),

12. 7018797 - Method for treating neurodegenerative disorders (2006-03-28),

13. 6995261 - 4-pyridazinecarboxamides and esters as interleukin-1β converting enzyme inhibitors (2006-02-07),

14. 6624166 - Pyridazines as interleukin-1&bgr; converting enzyme inhibitors (2003-09-23),

15. 6576614 - Peptide analogs as irreversible interleukin-1&bgr; protease inhibitors (2003-06-10),

Title: Tina Morgan Ross – Innovator in Pharmaceutical Patents

Introduction

Tina Morgan Ross, based in Royersford, PA, is a prolific inventor with an impressive portfolio of 24 patents. Her work primarily revolves around novel pharmaceutical compounds that address various medical conditions, particularly related to the central nervous system and hormonal disorders.

Latest Patents

Among her latest innovations is a patent for hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives, designed for the treatment of ORL-1 receptor mediated disorders. This innovative work showcases her commitment to developing solutions for complex medical issues. Another significant patent pertains to bridged aryl piperazine derivatives, which are pharmaceutical compositions aimed at treating depression and related disorders. These compounds function as serotonin transport inhibitors and modulators of 5HT, highlighting her contributions to mental health pharmaceuticals.

Career Highlights

Tina has made substantial contributions during her career, having worked with notable companies such as Janssen Pharmaceutica and Vertex Pharmaceuticals. Her expertise in drug development and innovative therapeutic solutions has positioned her as a key player in the pharmaceutical industry.

Collaborations

Throughout her career, Tina has collaborated with esteemed professionals in her field, including Allen B. Reitz and Roland Ellwood Dolle. These partnerships have undoubtedly enhanced her research capabilities and the impact of her inventions.

Conclusion

Tina Morgan Ross continues to be a significant force in pharmaceutical innovation. With her extensive patent portfolio and dedication to advancing medical treatments, she is poised to influence the future of therapeutic development substantially. Her journey in inventing novel compounds serves as an inspiration to both current and aspiring inventors in the field.

This text is generated by artificial intelligence and may not be accurate.